Obesity market news — August 11, 2026
The most important finding of the week is not about weight. A post hoc analysis of the SELECT Phase 3 trial, published in early August, followed 2,970 older participants with cardiovascular disease and overweight or obesity but without diabetes, and found that semaglutide slowed the worsening of a 25-protein blood signature that predicts future dementia risk. This is a biomarker result, not a clinical outcome: nobody has shown that fewer people went on to develop dementia. But it strengthens the argument that the cardiometabolic benefit of GLP-1 therapy reaches the brain, and it lands at a moment when Novo Nordisk needs a story that is not about the weight-loss race it is currently losing.
The second front opened this week is financial rather than scientific. Indiana confirmed it will cover GLP-1 medicines for obesity through the federal BALANCE model, with the state paying about 85 dollars per patient per month against a listed 245 dollars, the remainder carried by federal contributions and manufacturer discounts. Set against that, the number of state Medicaid programmes covering obesity medicines fell from sixteen in 2025 to thirteen at the start of 2026 as budget pressure pushed states out. Access is therefore not simply widening. It is being renegotiated, state by state, at a lower net price.
Altimmune moved its lead asset into late-stage development. On August 3 the company initiated PERFORMA, a global registrational Phase 3 trial of pemvidutide in MASH, testing fibrosis improvement and MASH resolution after the positive IMPACT Phase 2b data. Second quarter results follow on August 12. For a company whose obesity positioning rests on glucagon-driven fat loss with muscle preservation, MASH is the nearer regulatory path, and the market will read this quarter mainly for cash runway against two Phase 3 programmes.
Novo Nordisk (NVO): A post hoc analysis of the SELECT Phase 3 trial reported that semaglutide attenuated the worsening of a proteomic blood signature associated with future dementia risk, in 2,970 older adults with cardiovascular disease and overweight or obesity but without diabetes. The endpoint is a 25-protein signature, not diagnosed dementia, so the result is hypothesis-generating rather than practice-changing. It nonetheless extends the beyond-weight narrative that Novo needs after ziltivekimab missed its primary endpoint in ZEUS on July 31.
Altimmune (ALT): On August 3 Altimmune initiated PERFORMA, a global randomised, double-blind, placebo-controlled registrational Phase 3 trial of pemvidutide in MASH, evaluating fibrosis improvement, MASH resolution and clinical outcomes. It follows the 48-week IMPACT Phase 2b data presented at EASL earlier this year. Second quarter results are due on August 12, and with RECLAIM in alcohol use disorder also reading out positively on July 28, the company now carries several parallel programmes against a finite balance sheet.
Structure Therapeutics (GPCR): Aleniglipron drew broad media attention on August 10, when general-audience outlets picked up the Phase 2b ACCESS results published in Nature Medicine in June: mean weight reductions of 9.0, 10.7 and 12.1 percent at 45, 90 and 120 mg across 230 adults over 36 weeks, against 0.5 percent on placebo, with 10.4 percent discontinuation. This is coverage of existing data, not a new readout. The number that matters more is ACCESS II, where the 180 mg dose delivered 16.3 percent placebo-adjusted weight loss, and the Phase 3 programme remains guided to start in the third quarter of 2026, which is now.
Viking Therapeutics (VKTX): Viking confirmed that the Phase 3 VANQUISH-1 and VANQUISH-2 trials of subcutaneous VK2735 are fully enrolled and proceeding to plan, and that enrolment is complete in the maintenance dosing study, where patients retained the majority of their weight loss four weeks after the final dose. That supports the case for once-monthly maintenance, a genuine differentiator if it holds. Phase 3 for the oral formulation is guided to begin in the fourth quarter of 2026, funded from a 502 million dollar cash position.
Hims & Hers (HIMS): The clearest commercial signal of the week came from outside the developers. Hims & Hers reported second quarter revenue of about 753 million dollars, up 38 percent, with subscribers near 2.9 million, but a net loss of 37 cents per share against an expected 1 cent, and gross margin down to 64 percent from 76 percent a year earlier. The cause is the shift from compounded to branded GLP-1s. Full year revenue guidance was raised to 3.1 to 3.3 billion dollars. For the manufacturers this is confirmation that the branded channel is being fed; for the telehealth layer it shows who absorbs the margin.
Eli Lilly (LLY): Lilly continued to benefit from the post-earnings repricing, with analysts raising fair value estimates on the strength of the GLP-1 franchise and the shares gaining 3.9 percent on August 10. There was no new clinical or regulatory event this week. The company reported second quarter revenue up 48 percent to 23.0 billion dollars on August 5, and the market is still absorbing what that run rate implies for orforglipron and the oral segment.
Zealand Pharma (ZEAL): A quiet week. Petrelintide, the once-weekly amylin analogue partnered with Roche, remains on its path towards Phase 3 in chronic weight management, and the tolerability profile continues to be the asset's main argument against the incretin field. No new data or regulatory step was reported.
Amgen (AMGN): No news of substance after last week's move, when the company discontinued early development of an obesity candidate on August 4 while raising full-year guidance. MariTide, the monthly injectable, remains the programme that determines whether Amgen stays a credible third force in the field.